Arrowhead Pharma announces press release on plozasiran Phase 3 SHASTA-3 and SHASTA-4 topline results

Reuters2026/07/22 11:30

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Arrowhead released topline Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran in severe hypertriglyceridemia, meeting the primary triglyceride endpoint.
Median triglycerides fell 79% and 81% at month 12 versus about 27% with placebo.
Pooled analysis showed a statistically significant drop in acute pancreatitis events; high-risk subgroup showed a 100% reduction versus placebo.
Arrowhead plans a U.S. sNDA for the severe hypertriglyceridemia indication before end-2026.
Full data set for ESC Congress Aug. 30, 2026; slides to post on Arrowhead’s Events and Presentations page.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607220730BIZWIRE_USPR_____20260722_BW499878) on July 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Arrowhead Pharma announces press release on plozasiran Phase 3 SHASTA-3 and SHASTA-4 topline results

You may also like

Crypto prices